Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05570721
Other study ID # 22-0763
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 16, 2022
Est. completion date October 5, 2024

Study information

Verified date January 2024
Source University of North Carolina, Chapel Hill
Contact Margo Nathan, MD
Phone 919-962-9908
Email margo_nathan@med.unc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Depression is a known risk factor for cardiovascular disease (CVD), and this comorbidity contributes significantly to the morbidity and mortality of women. The menopausal transition or perimenopause is a period of vulnerability for both depression and CVD, making it a key time to study this critical public health issue. This research will preliminarily explore whether disruption in two novel stress pathways 1) the renin-angiotensin-aldosterone system (RAAS) and autonomic nervous system (ANS) and their relationship may underlie the link between these illnesses. Findings will provide important insight into potential mechanisms by which depression during perimenopause may increase risk for CVD in midlife women, which will inform potential risk reduction and treatment strategies that can improve health outcomes in this population.


Description:

This study uses an experimental stress task to induce mild social stress and activation of two physiological stress pathways (the RAAS and ANS) that may be be involved in the association between perimenopausal depression and risk for cardiovascular disease in women. Perimenopausal women with mild-moderate depressive symptoms and healthy women without any psychiatric history will be enrolled. All participants will complete the same study procedures. During the first visit (conducted remotely) consent will be obtained. After consent, participants will answer questions about their psychiatric history as part of a standardized psychological assessment (the Mini International Neuropsychiatric Interview) and medical/reproductive history, including current medications. They will also complete brief questionnaires about their current mood symptoms and history of exposure to trauma. Risk for self-harm using the Columbia Suicide Severity Rating Scale (CSSRS) will be assessed. After it is determined that a participant is eligible based on these assessments, she will then be given instruction for how to prepare for the second study visit, including refraining from exercise, alcohol, caffeine for at least 4 hours prior to the visit. Dietary education is also provided and participants are asked to keep a food journal for 3 days prior to the second study visit to standardize nutritional content prior to the second study visit. During the second visit (conduced in-person in a laboratory setting) participants will complete a brief stress task. All of these visits will be conducted between 2-6 in the afternoon/evening.This visit will have four components: 1. Orientation: participants will be oriented to the study visit and taught how to do the saliva collection. Height and weight will be measured and a urine pregnancy test completed. The CSSRS will be repeated for safety. 2. Rest period: this includes a 30-minute resting period in the seated position. Participants will complete self-report questionnaires on mood, anxiety, sleep and menopausal symptoms. 2 electrocardiogram (EKG) leads and nodes will be applied for the heart rate monitoring portion. During any residual time white noise will be played and the lights dimmed to promote relaxation. 3. Completion of the stress task (the Trier Social Stress Test or TSST): this task involves social evaluation, speech, and math related stress and takes approximately 15 minutes to complete. Participants are introduced to a 1-2-person committee. The participant will assume the role of a job applicant who is invited for a personnel interview with the committee. Anticipation: The participant prepares for 5 minutes. Speech (5 mins): The committee asks the participant to deliver her talk for 5 minutes. The committee responds with prepared questions to ensure that the talk lasts for 5 minutes. Serial Subtraction (5 mins): The committee members will give the participant a number to start from and then ask them to subtract a number from that original number and then continue to subtract that same number, saying aloud the answers until they get to zero. 4. Recovery and debriefing: during this phase the participant rests alone. After recovery is complete the study team will debrief with the participant about the nature of stress task and answer any questions. Sample collection: blood and saliva will be collected immediately prior to and following the stress task. Saliva is also collected at 10 and 20 minutes after the stress task. Heart rate will be measured through the duration of the stress task and recovery period. The third visit includes a brief telephone call with the principal investigator to review participation in the study and answer any questions.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date October 5, 2024
Est. primary completion date October 5, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 44 Years to 55 Years
Eligibility Inclusion Criteria: - Women ages 44-55 in the late perimenopause reproductive phase. Perimenopausal status will be determined based on menstrual cycle history. We will enroll women who have had an interval of amenorrhea of at least 60 days but <1 year consistent with the late menopause transition - Participants in either group may be on antidepressant medications (for any indication), but doses must be stable within 30 days of study participation Exclusion Criteria: - History of bipolar diagnosis or primary psychotic disorder for both groups; prior history of depression in the no-perimenopausal depression group - In the perimenopausal depression group, current depressive symptoms that are "severe" based on score of Center for Epidemiologic Studies Depression Scale (CES-D) >25. - Current alcohol or substance use disorder - Current suicidal ideation with intent and history of suicide attempt within 2 years of study participation - Current or recent use of the following medications: 1. Hormonal agents (e.g., hormone replacement therapy or combined oral contraceptive pills)within the past 30 days 2. Oral, inhaled, or injected steroids within the past 90 days 3. Blood pressure medications (e.g., Angiotensin-Converting Enzyme (ACE) inhibitors) within the past 90 days 4. Antihistamines within the past two weeks 5. Other medications determined by the study team to impact the RAAS (e.g., spironolactone). - Current cigarette or nicotine use - Current diagnosis of cardiovascular disease, type I or II diabetes, or other medical condition which the study team determines could impact study outcomes

Study Design


Intervention

Behavioral:
Trier Social Stress Test
The TSST has both social-evaluative and arithmetic components. During the social-evaluative component, the participant is asked to prepare and then deliver a brief speech to the research team. After this component there is a surprise arithmetic problem. This challenge paradigm has been well-established to rapidly and robustly induce psychological stress as well as physiological indices of stress (e.g., cortisol response, heart rate response). This task takes approximately 15 minutes to complete.

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill The Foundation of Hope for Research and Treatment of Mental Illness

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Salivary aldosterone (pg/mL) levels at rest (before the stress task). Examine variability in salivary aldosterone levels (pg/mL) by calculating medians. Immediately prior to the stress task.
Primary Change in salivary aldosterone (pg/mL) levels in response to the stress task. Examine variability in salivary aldosterone levels (pg/mL) in response to the TSST. Immediately prior to the stress task and at intervals of 0, 10, and 20 minutes after the stress task.
Primary Plasma aldosterone (pg/mL) levels at rest (before the stress task). Examine variability in plasma aldosterone levels (pg/mL) by calculating medians. Immediately prior to the stress task.
Primary Change in plasma aldosterone (pg/mL) levels in response to the stress task. Examine variability in plasma aldosterone levels (pg/mL) in response to the TSST. Immediately prior to and at 0 minutes after the stress task.
Primary Plasma angiotensin II (pg/mL) levels at rest (before the stress task). Examine variability in plasma angiotensin II levels (pg/mL) by calculating medians. Immediately prior to the stress task.
Primary Change in plasma angiotensin II (pg/mL) levels in response to the stress task. Examine variability in plasma angiotensin II levels (pg/mL) in response to the TSST. Immediately prior to and at 0 minutes after the stress task.
Primary Plasma renin (pg/mL/hr) levels at rest (before the stress task). Examine variability in plasma renin levels (pg/mL/hr) by calculating medians. Immediately prior to the stress task.
Primary Change in plasma renin (pg/mL/hr) levels in response to the stress task Examine variability in plasma renin levels (pg/mL/hr) in response to the TSST. Immediately prior to and at 0 minutes after the stress task
Secondary Heart rate variability defined as the root mean square of successive differences (RMSSD) between normal heartbeats in ms values at rest (before the stress task). Examine variability in RMSSD values measured at rest. Epoch recorded immediately before the stress task.
Secondary Change in heart rate variability defined as the root mean square of successive differences (RMSSD) between normal heartbeats in ms in response to the stress task. Examine variability in RMSSD values measured in response to the TSST. Epochs recorded immediately before the stress task and intervals of 0, 10, and 20 minutes after the stress task.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A